Key Considerations for Maximizing AAV and LV Production in Transient Transfection Workflows
Email alerts
Free registration
Chat area
Certificate of attendance
Transient transfection is a critical component for enabling high titer, large-scale viral vector manufacturing processes.
Mirus Bio will present optimization strategies for AAV and LV production in adherent and suspension HEK 293 cells with the TransIT-VirusGEN® Transfection Reagent. We will also discuss LV and AAV enhancers that further increase functional virus titers and expand manufacturing capabilities for gene and cell therapies.
Presented by
Leisha Kopp
Leisha Kopp is an Applications Scientist at Mirus Bio LLC, a biotech company providing innovative transfection products to cell culture researchers worldwide. Leisha has over 15 years of molecular biology and mammalian cell culture experience in industrial labs, which enables her to support of scientists in all stages of the drug discovery process - from R&D to commercial manufacturing. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in biotherapeutic antibody discovery and gene therapy.